Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind?

Por Aletaha, Daniel
Publicado em 2006

Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data

Por Aletaha, Daniel
Publicado em 2009

From the item to the outcome: the promising prospects of PROMIS

Por Aletaha, Daniel
Publicado em 2010

Nothing lasts forever - a critical look at sustained remission

Por Aletaha, Daniel
Publicado em 2012

The many faces of psoriatic arthritis – a challenge to treatment to target?

Por Aletaha, Daniel
Publicado no Reumatologia (2016)

Developments in the clinical understanding of rheumatoid arthritis

Por Smolen, Josef S, Aletaha, Daniel
Publicado em 2009

Treating rheumatic patients with a malignancy

Por Elandt, Katarzyna, Aletaha, Daniel
Publicado em 2011

Considering comorbidity in managing rheumatic diseases: going where trials cannot go

Por Aletaha, Daniel, Dörner, Thomas
Publicado em 2011

Therapeutic implications of autoantibodies in rheumatoid arthritis

Por Aletaha, Daniel, Blüml, Stephan
Publicado no RMD Open (2016)

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs

Por Radner, Helga, Smolen, Josef S, Aletaha, Daniel
Publicado em 2014

Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials

Por Aletaha, Daniel, Alasti, Farideh, Smolen, Josef S.
Publicado no Arthritis Res Ther (2015)

Disease activity level, remission and response in established rheumatoid arthritis: Performance of various criteria sets in an observational cohort, treated with anti-TNF agents

Por Gülfe, Anders, Aletaha, Daniel, Saxne, Tore, Geborek, Pierre
Publicado em 2009

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruct...

Por Smolen, Josef S, Avila, José C Martinez, Aletaha, Daniel
Publicado em 2011

Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients

Por Radner, Helga, Alasti, Farideh, Smolen, Josef S., Aletaha, Daniel
Publicado no Arthritis Res Ther (2015)

An overview of psoriatic arthritis – epidemiology, clinical features, pathophysiology and novel treatment targets

Por Kerschbaumer, Andreas, Fenzl, Karl H., Erlacher, Ludwig, Aletaha, Daniel
Publicado no Wien Klin Wochenschr (2016)

Value of self-performed joint counts in rheumatoid arthritis patients near remission

Por Radner, Helga, Grisar, Johannes, Smolen, Josef S, Stamm, Tanja, Aletaha, Daniel
Publicado em 2012

Fever of unknown origin (FUO) revised

Por Unger, Manuel, Karanikas, Georgios, Kerschbaumer, Andreas, Winkler, Stefan, Aletaha, Daniel
Publicado no Wien Klin Wochenschr (2016)

Analysis of gene expression in rheumatoid arthritis and related conditions offers insights into sex-bias, gene biotypes and co-expression patterns

Por Platzer, Alexander, Nussbaumer, Thomas, Karonitsch, Thomas, Smolen, Josef S., Aletaha, Daniel
Publicado no PLoS One (2019)

Pseudoerosions of Hands and Feet in Rheumatoid Arthritis: Anatomic Concepts and Redefinition

Por Hirtler, Lena, Rath, Claus, Platzgummer, Hannes, Aletaha, Daniel, Kainberger, Franz
Publicado no J Clin Med (2019)

The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?

Por Smolen, Josef S, Aletaha, Daniel, Grisar, Johannes, Redlich, Kurt, Steiner, Günter, Wagner, Oswald
Publicado em 2008